Trials / Completed
CompletedNCT01081782
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 407 (actual)
- Sponsor
- Ono Pharma USA Inc · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-4641 | 0.15 mg once per day for 26 weeks |
| DRUG | ONO-4641 | 0.1 mg once per day for 26 weeks |
| DRUG | ONO-4641 | 0.05 mg once per day for 26 weeks |
| DRUG | ONO-4641 placebo | Placebo once per day for 26 weeks |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2010-03-05
- Last updated
- 2013-12-25
Locations
86 sites across 11 countries: United States, Belgium, Canada, Czechia, Germany, Greece, Japan, Poland, Russia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT01081782. Inclusion in this directory is not an endorsement.